---
layout: default
title: Alpha Lipoic Acid Cholesterol Cortisone Acetate Co
parent: 僅模型預測 (L5)
nav_order: 257
evidence_level: L5
indication_count: 0
---

# Alpha Lipoic Acid Cholesterol Cortisone Acetate Co
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Preparation: No Repurposing Prediction Available

## One-Sentence Summary

This candidate is a 20-component preparation comprising herbal, animal, mineral, and pharmacological ingredients (including Alpha Lipoic Acid, Rauwolfia Serpentina, Lachesis Muta Venom, Nitroglycerin, and Veratrum Album Root, among others).
No original registered indication, no DrugBank identifier, and no TxGNN predicted new indication are available, making a full repurposing evaluation impossible at this stage.
Without a valid drug node mapping, this candidate cannot be progressed through the standard pipeline.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None — no TxGNN prediction generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | — |
| Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This preparation contains 20 distinct ingredients spanning radically different pharmacological classes:

| Category | Components |
|----------|-----------|
| Antioxidant / metabolic | Alpha Lipoic Acid |
| Cardiovascular agents | Nitroglycerin, Rauwolfia Serpentina |
| Steroid | Cortisone Acetate |
| Catecholamine | Epinephrine |
| Animal venom | Lachesis Muta Venom |
| Plant extracts | Garlic, Coumarin, Veratrum Album Root, Selenicereus Grandiflorus Stem |
| Mineral compounds | Gold, Sulfur, Strontium Carbonate, Potassium Chlorate, Cholesterol |
| Biological / tissue-derived | Sus Scrofa Artery, Sus Scrofa Vein, Thyroid |
| Antimicrobial antigen | Proteus Vulgaris |
| Preservative / fixative | Formaldehyde Solution |

This combination is characteristic of a **homeopathic or anthroposophic formulation**. Such preparations are typically not represented as a single node in the TxGNN knowledge graph (DrugBank ID: not found), which is why the model was unable to generate a repurposing prediction.

Evaluating the preparation as a whole is not feasible under the current TxGNN framework. Individual components (e.g., Nitroglycerin, Rauwolfia Serpentina) do have established pharmacology and could in principle be evaluated separately, but that falls outside the scope of this candidate record.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This multi-component preparation lacks a DrugBank identifier, has no registered indication, and produced no TxGNN repurposing prediction, making it ineligible for evaluation under the standard pipeline in its current form.

**To proceed, the following is needed:**

- **Clarify product identity**: Confirm whether this is a homeopathic/anthroposophic combination product and obtain the manufacturer name and product registration history
- **Establish a drug node**: Map the preparation (or its principal active component) to a valid DrugBank ID or equivalent knowledge graph node before re-running TxGNN
- **Retrieve original indication(s)**: Obtain historical registration records or manufacturer documentation
- **Obtain MOA data**: Mechanism of action data for the preparation or its dominant pharmacologically active components
- **Retrieve safety data**: Download and parse the package insert to extract warnings and contraindications (currently Blocking per DG001)
- **Consider component-level analysis**: If a unified mapping cannot be established, evaluate clinically relevant individual components (e.g., Nitroglycerin, Rauwolfia Serpentina) as separate candidates
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

